Wet Age-related Macular Degeneration Market is Expected to Grow at a CAGR of 6.6% by 2034

According to DelveInsight’s analysis, the total Wet Age-related Macular Degeneration (Wet AMD) market size across the 7MM was valued at approximately USD 7,783 million, reflecting the growing economic burden and therapeutic demand associated with this vision-threatening condition. The United States accounted for the largest market share, representing nearly 33% of the total Wet AMD market, driven by a high diagnosed patient pool, early adoption of innovative therapies, and widespread access to advanced ophthalmic care. Within Europe, Germany emerged as the leading market, contributing around USD 1,313 million, owing to a robust healthcare infrastructure, high awareness levels, and extensive use of anti-VEGF therapies. In contrast, Spain recorded the lowest market size among the European countries, estimated at approximately USD 353 million, indicating regional differences in diagnosis rates and treatment penetration. Meanwhile, Japan held a significant share of the global Wet AMD market, supported by a substantial disease prevalence and rapid adoption of emerging treatment modalities, positioning it as a key growth region in the evolving Wet AMD landscape.

Understanding Wet Age-related Macular Degeneration (Wet AMD)

Wet Age-related Macular Degeneration (Wet AMD), also known as neovascular AMD, is a severe and progressive retinal disease characterized by the abnormal growth of fragile blood vessels beneath the macula. These vessels leak blood and fluid, leading to swelling, scarring, and rapid central vision loss. Although Wet AMD accounts for only around 10% of total AMD cases, it is responsible for approximately 90% of AMD-related central vision loss.

The macula, located in the central retina, is critical for sharp, detailed vision. When damaged, patients experience blurred or distorted central vision, making tasks such as reading, driving, or recognizing faces increasingly difficult. As the global population continues to age, the burden of Wet AMD is expected to rise significantly, posing serious challenges for patients, caregivers, and healthcare systems worldwide.

DelveInsight, has released its latest report, “Wet Age-Related Macular Degeneration Market Insights, Epidemiology, and Market Forecast – 2034”. The comprehensive study provides an in-depth understanding of the Wet Age-Related Macular Degeneration (Wet AMD) treatment landscape, covering current and emerging therapies, clinical trials, regulatory approvals (EMA, FDA, PMDA, NICE), market dynamics, prevalence trends, and competitive insights across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

For an in-depth analysis of the Wet AMD market, including competitive landscape, pipeline therapies, and epidemiology, Download the Full Report Here.

Wet Age-Related Macular Degeneration Market Overview

Wet Age-Related Macular Degeneration (Wet AMD) is a progressive retinal disease caused by abnormal growth of blood vessels beneath the retina, often leading to vision loss. With an aging population globally, Wet AMD prevalence is rising rapidly. DelveInsight’s analysis highlights a significant unmet need, despite advancements in anti-VEGF therapies and new gene-based treatments under clinical evaluation.

The Wet Age-Related Macular Degeneration treatment market is projected to grow considerably during the forecast period (2020–2034), driven by:

• Increasing patient pool due to aging demographics.
• Pipeline breakthroughs with gene therapies and long-acting biologics.
• Strategic regulatory approvals by EMA, FDA, PMDA, and NICE.
• Market expansion in 7MM supported by healthcare policy reforms and R&D investments. 

Explore current and emerging therapies, market dynamics, and growth projections by Requesting a Sample of the Wet AMD Report

Wet Age-Related Macular Degeneration Future Outlook:

• Market growth expected with new therapies: OPT-302 (Opthea), KSI-501 (Kodiak Sciences), RGX-314 (Regenxbio) and others.
• Increasing prevalence and innovative long-acting treatments will expand the Wet AMD market size in the coming years.

Key Wet Age-Related Macular Degeneration Epidemiology Insights

DelveInsight’s epidemiological assessment reveals striking figures that underscore the future potential of the Wet AMD market:

• The total diagnosed prevalent cases of AMD across the seven major markets (7MM) reached nearly 40 million in 2023.
• The United States accounted for the highest share with approximately 14 million cases in 2023, followed by Japan (~8 million) and Germany (~6 million).
• Within Europe, Germany had the highest Wet AMD prevalence (~595,000), while Spain reported the lowest (~160,000).
• Japan’s Wet AMD prevalence reached ~840,000 cases in 2023, representing nearly 21% of the 7MM burden.
• Age-specific segmentation indicated that in the US, patients aged 70–79 years had the highest prevalence (~407,000 cases in 2023).
• The analysis highlights that Dry AMD remains more common in Japan (90% of total cases) compared to Wet AMD (10%).
• These data illustrate not only the size of the existing burden but also the potential for market expansion as awareness, diagnostics, and treatment access improve across regions.

 

Current and Emerging Wet Age-Related Macular Degeneration Therapies

Wet Age-Related Macular Degeneration Marketed Drugs

1.       EYLEA (Aflibercept) – Regeneron Pharmaceuticals

o   Injectable VEGF inhibitor for Wet AMD, with ongoing Phase III trials testing extended dosing regimens.

2.       BEOVU (Brolucizumab) – Novartis

o   Anti-VEGF therapy offering dosing flexibility of up to 12 weeks.

3.       VABYSMO (Faricimab) – Roche/Genentech

o   First bispecific antibody targeting both Ang-2 and VEGF-A pathways.

These agents remain the backbone of Wet AMD treatment, with ongoing label expansions and post-marketing trials aimed at optimizing dosing and improving durability.

Wet Age-Related Macular Degeneration Emerging Drugs in Pipeline

• OPT-302 (Opthea Limited) – A VEGF-C/D inhibitor designed to complement anti-VEGF-A therapies.
• KSI-501 (Kodiak Sciences) – Novel biologic providing extended VEGF inhibition for long-term efficacy.
• RGX-314 (Regenxbio) – Gene therapy candidate administered via subretinal or suprachoroidal delivery.
• EYP-1901 (EyePoint Pharmaceuticals) – Sustained-release anti-VEGF therapy under Phase II development.
• ALK4290 (Alkahest) – Small molecule targeting inflammatory pathways in retinal diseases.

The late-stage pipeline reflects a paradigm shift from frequent intravitreal injections toward longer-acting biologics and gene therapies that aim to reduce treatment burden and improve compliance.

Recent Developments in Wet Age-Related Macular Degeneration Clinical Trials

• In August 2025, Outlook Therapeutics announced that the FDA issued a complete response letter (CRL) for its biologics license application for the treatment of wet age-related macular degeneration (wet AMD), indicating the application cannot be approved in its current form.
• In April 2025, Outlook Therapeutics announced that the U.S. FDA has received the resubmitted Biologics License Application (BLA) for ONS-5010 (bevacizumab-vikg), an investigational ophthalmic bevacizumab formulation for treating wet age-related macular degeneration (wet AMD).

Discover detailed insights on clinical trials, drug pipelines, and regulatory updates by Requesting Expert Analysis.

Wet Age-Related Macular Degeneration Market Dynamics and Trends

Wet Age-Related Macular Degeneration Market Drivers

• Rising global prevalence of Wet AMD due to aging demographics.
• Regulatory support for expedited approvals (EMA, FDA, PMDA, NICE).
• Increased R&D investment in ophthalmology therapeutics.
• Adoption of gene therapies and bispecific antibodies

Wet Age-Related Macular Degeneration Market Barriers

• High treatment costs limiting access in low-income markets.
• Need for frequent intravitreal injections affecting compliance.
• Competition among biologics leading to pricing pressures.
• Complexity of long-term efficacy validation in real-world settings.

Wet Age-Related Macular Degeneration Competitive Landscape

DelveInsight’s report profiles leading Wet AMD companies shaping the future market, including:

• Opthea Limited
• Outlook Therapeutics
• Kodiak Sciences
• Regenxbio
• Dobecure
• Gemini Therapeutics
• Huabo Biopharm
• Isarna Therapeutics
• IVERIC bio (formerly Ophthotech Corporation)
• Ribomic
• Curacle
• Bio-Thera Solutions
• AngioLab Inc.
• Alkahest
• Tyrogenex
• Iconic Therapeutics
• AiViva BioPharma
• Boehringer Ingelheim
• RemeGen
• And several others.

Wet Age-Related Macular Degeneration Market Outlook (2020–2034)

DelveInsight projects that the Wet Age-Related Macular Degeneration market size will grow at a considerable CAGR across the 7MM during the study period. Growth will be fueled by:

• Increased patient population in the aging demographic.
• Launch of emerging therapies such as RGX-314, OPT-302, and KSI-501.
• Extended durability of treatment reducing patient burden.
• Broader reimbursement access through NICE, EMA, FDA, and PMDA-backed policies.

Scope of the Wet Age-Related Macular Degeneration Market Report

• Coverage: 7MM (US, EU5, Japan)
• Study Period: 2020–2034
• Companies Covered: Opthea Limited, Outlook Therapeutics, Kodiak Sciences, Regenxbio, IVERIC bio, Ribomic, Curacle, Bio-Thera Solutions, AngioLab Inc., Alkahest, Tyrogenex, Boehringer Ingelheim, RemeGen, and others.
• Pipeline Therapies: RGX-314, Tarcocimab Tedromer, Aflibercept, KSI-301, EYP-1901, ALK4290, etc.
• Focus Areas: Epidemiology, market dynamics, therapies, regulatory approvals, unmet needs, reimbursement strategies, and SWOT analysis.

For actionable insights on market expansion and pipeline strategies, Connect with DelveInsight Experts

About DelveInsight

DelveInsight is a leading healthcare-focused market research and consulting firm, delivering actionable intelligence across life sciences. Our expertise spans market analysis, epidemiology forecasting, competitive intelligence, and pipeline assessments empowering stakeholders to make informed strategic decisions.